Trial Profile

A non-interventional real world study assessing the long-term effectiveness and safety of siponimod as well as its impact on quality of life in patients secondary progressive multiple sclerosis

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2024 Planned number of patients changed to 670.
02 Mar 2024 Interim Results (n=240) assessing effectiveness and safety of siponimod for the treatment of patients suffering from active SPMS in a real-world setting presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
27 Apr 2023 Results (n=600) assessing long-term effectiveness and safety of siponimod presented at the 75th Annual Meeting of the American Academy of Neurology 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com